Infectious Disease

NIH commences tuberculous meningitis drug combination regimen trial

The US National Institutes of Health (NIH) has commenced the Phase II IMAGINE-TBM clinical trial of a new drug combination…

Viriom outlines plans for upcoming infectious disease trials

Viriom plans to extend a Phase I trial investigating its influenza pill AV5124, according to chief science officer Dr David…

World AIDS Day 2023 highlights community leadership to end the HIV epidemic

1 December commemorates World AIDS Day – a day of awareness and support for those living with HIV/AIDS, as well…

Merck reports data from Phase III pneumococcal vaccine trial

Merck (MSD) has reported data from the Phase III STRIDE-3 clinical trial of its investigational 21-valent pneumococcal conjugate vaccine, V116, for usage…

Vaxxas reports positive data from MR vaccine trial

Vaxxas has reported positive results from a Phase I clinical trial for the measles and rubella (MR) vaccine, which was…

Medicure approved to enrol patients in paediatric disease trial

Canadian pharmaceutical company Medicure has received full approval from the US Food and Drug Administration (FDA) to enrol subjects in…

Berlin Cures announces expansion of long Covid drug study

Swiss biopharmaceutical company Berlin Cures has announced the expansion of the Phase II clinical trial of its long Covid drug…

University of Queensland’s vaccine shows virus-neutralising effect in trial

The University of Queensland (UQ) in Australia has reported that its second-generation clamp vaccine demonstrated to be safe and possesses…

AIM ImmunoTech concludes dosing in Phase II post-Covid drug trial

AIM ImmunoTech has concluded subject dosing in the Phase II clinical trial of its investigational drug, Ampligen, to treat individuals with post-Covid…

FDA grants IND approval for Senhwa’s trial of Silmitasertib 

The US Food and Drug Administration (FDA) has granted approval for Senhwa Biosciences’ investigational new drug application (IND) to commence a Phase…

close

Sign up to the newsletter: In Brief

Your corporate email address *
First name *
Last name *
Company name *
Job title *
Vist our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close